BUSINESS

Astellas Makes Full Inroads into I/O Arena with Potenza Buyout

December 17, 2018
Astellas Pharma decided to wade into the red-hot development space of immuno-oncology by exercising an option it acquired three and a half years ago to buy out US biotech startup Potenza Therapeutics, making it a wholly owned subsidiary, for US$164.6…

To read the full story

Related Article

BUSINESS

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…